Adma Biologics Inc (NASDAQ: ADMA) kicked off on Friday, down -4.61% from the previous trading day, before settling in for the closing price of $12.26. Over the past 52 weeks, ADMA has traded in a range of $3.06-$14.03.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 73.26% over the past five years. While this was happening, its average annual earnings per share was recorded 371.15%. With a float of $223.88 million, this company’s outstanding shares have now reached $226.06 million.
Let’s look at the performance matrix of the company that is accounted for 624 employees.
Adma Biologics Inc (ADMA) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adma Biologics Inc is 3.42%, while institutional ownership is 75.30%. The most recent insider transaction that took place on Jun 14 ’24, was worth 1,071,980. In this transaction President,CEO, and Interim CFO of this company sold 100,000 shares at a rate of $10.72, taking the stock ownership to the 2,081,475 shares. Before that another transaction happened on Mar 19 ’24, when Company’s Director sold 411,829 for $6.08, making the entire transaction worth $2,503,920. This insider now owns 2,115,671 shares in total.
Adma Biologics Inc (ADMA) Latest Financial update
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.03 earnings per share (EPS), lower than consensus estimate (set at -0.02) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 371.15% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Take a look at Adma Biologics Inc’s (ADMA) current performance indicators. Last quarter, stock had a quick ratio of 1.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.57. Likewise, its price to free cash flow for the trailing twelve months is 168.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.02, a number that is poised to hit 0.08 in the next quarter and is forecasted to reach 0.54 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Adma Biologics Inc (NASDAQ: ADMA) saw its 5-day average volume 3.73 million, a positive change from its year-to-date volume of 2.91 million. As of the previous 9 days, the stock’s Stochastic %D was 17.53%. Additionally, its Average True Range was 0.53.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 71.29%, which indicates a significant increase from 11.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.30% in the past 14 days, which was lower than the 50.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.40, while its 200-day Moving Average is $6.80. Nevertheless, the first resistance level for the watch stands at $12.00 in the near term. At $12.30, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.61. If the price goes on to break the first support level at $11.39, it is likely to go to the next support level at $11.08. The third support level lies at $10.78 if the price breaches the second support level.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
The company with the Market Capitalisation of 2.71 billion has total of 231,809K Shares Outstanding. Its annual sales at the moment are 258,220 K in contrast with the sum of -28,240 K annual income. Company’s last quarter sales were recorded 81,880 K and last quarter income was 17,810 K.
